February 3, 2010 (FinancialWire) — Access Pharmaceuticals, Inc. (OTCBB: ACCP), said that it has closed the sale of around 2.10 million shares of its common stock and warrants to purchase around 1.05 million shares of its common stock for gross proceeds of around $6.3 million.

The company sold the shares and warrants for $3.00 per unit, with each unit consisting of one share and a warrant to purchase 0.5 shares of common stock. The exercise price of the warrants is $3.00 per share.

Dallas-based Access Pharmaceuticals is an emerging biopharmaceutical company that develops and commercializes propriety products for the treatment and supportive care of cancer patients.

FinancialWire(tm) is committed to serving the financial community through true journalism and providing relevant resources to investors. Standards-based, independent equity research on numerous public companies is available through the Investrend Research Syndicate (http://www.investrend.com/reports) written by FIRST Research Consortium (http://www.investrend.com/FIRST) member-providers. Free annual reports and company filings for companies mentioned in the news are available through the Investrend Information Syndicate (at http://investrend.ar.wilink.com/?level=279). FinancialWire(tm), in cooperation with the Investrend Broadcast Syndicate, also provides complete, daily conference call and webcast schedules as a service to shareholders and investors via the FirstAlert(tm) Network’s “FirstAlert(tm) Daily” (http://www.financialwire.net/news-alerts/).

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) website (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.